FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:329-331 August 4, 1994 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Peters, W. P. Related Article by Boren, S. D.

To the Editor: In concluding that the current process for making decisions about coverage of high-dose chemotherapy for breast cancer is "arbitrary and capricious," Drs. Peters and Rogers (Feb. 17 issue)¹ assume that . . . only insurers have a financial interest in making determinations about coverage. At the commonly quoted price of $150,000 per course of treatment, however, treatment of the 533 women in their analysis represents an annual income of $20 million to their institution alone. Institutions, providers, and suppliers all benefit substantially from insurance coverage for this treatment.

Though the authors indicate otherwise, publication of their article . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Ehrlich, M. P., Nienaber, C. A., Rousseau, H., Beregi, J.-P., Piquet, P., Schepens, M., Bartoli, J.-M., Schillinger, M., Fattori, R. (2008). Short-term conversion to open surgery after endovascular stent-grafting of the thoracic aorta: The Talent thoracic registry.. J. Thorac. Cardiovasc. Surg. 135: 1322-1326 [Abstract] [Full Text]